Expression of PSMA in Thyroid follicular neoplasms: Utility for differentiating between benign from malignant lesions
Keywords:
Angiogenesis, Prostate-Specific Membrane Antigen, Thyroid Follicular Adenoma, Thyroid Follicular CarcinomaAbstract
Back ground: Prostate-Specific membrane Antigen has been known as a tumor associated neovasculature marker in some solid malignant tumors and targeting of that by cytotoxic- conjugated antibody can represent powerful tool for vascular targeted therapy in malignant tumors. In thyroid, it appears that angiogenesis factors are involved in neoplastic growth and aggressiveness of tumors.
This study was conducted to evaluate the expression of PSMA as an angiogensis factor by immunohistochemistry in neovasculature of thyroid follicular neoplasms to determine its usefulness for distinguishing between adenoma and carcinoma .
Methods: Paraffin Blocks of formalin fixed samples representing 48 cases of Follicular Thyroid adenoma and 15 cases of Follicular Thyroid Carcinoma were evaluated.
Results: Among Carcinomas, capsular and vascular invasion were present in 12 and 11 cases , respectively.
The intensity of PSMA staining was significantly higher in carcinoma group(p=0.028). However, no significant difference in extent of PSMA expression in adenoma and carcinoma groups was observed(p=0.239).Thyroid follicular cells in adenoma, carcinoma also non neoplastic area were negative for PSMA.
Conclusion: Our findings do not support usefulness of PSMA in differentiating between FTA and FTC. However ; expression in neovasculature of differentiated thyroid tumors can represent a potential utility for PSMA-targeted radionuclide therapy in advanced differentiated thyroid cancers.
DOI:10.21276/APALM.1511
References
1. Wartofsky L. Increasing world incidence of thyroid cancer: Increased detection or higher radiation exposure?Hormones.2010;9(2): 103-108.
2. Kebebew E., Peng M, Reiff E, Duh Q, Clark O, McMillan A.Diagnostic and Prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.Surgery.2005;138: 1102-10.
3. Duggal R, Rajwanshi A, Gupta N, Vasishta R. K.Interobserver variability amongst cytopathologists and histopathologists in the diagnosis of neoplastic follicular patterened lesions of thyroid". Diagn Cytopathol.2011;39(4): 235-241.
4. Sanii S., Saffar H, Moradi Tabriz H, Qorbani M, Haghpanah V, Tavangar S. M.Expression of Matrix Metalloproteinase-2, but not Caspase-3, Facilitates Distinction between Benigsn and malignant thyroid follicular neoplasm.Asian PacJ Cancer Prev.2012;13:
5. Yoon JH., Kim E.K, Youk J. H., Moon H. J., Kwak J. Y. Better understanding in the differentiation of thyroid folicular adenoma , follicular carcinoma, and follicular variant of papillary carcinoma: A retrospective study.Int J Endocrinol. 2014; ID 321595: (http://dx.doi.org/10.1155/2014/321595).
6. JehS.K.,So L. J., Bum S. K., Yoen S. L. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor.Korean J Radiol. 2007;8(3): 192-197.
7. Jogai S., Adesina AO., Temmim L., Al-Jassar A., Amir T., Amanguno HG. Follicular variant of papillary thyroid carcinoma-a cytological study.Cytopathology. 2004;15(4): 212-216.
8. Vasko VV., Gaudart C, Allasia C. et al.Thyroid follicular adenomas may display features of follicular carcinoma and folicular variant of papillary carcinoma.Eur J Endocrinol.2004;151(6): 79-786.
9. Manivannan P. Siddaraju N., Jatia L., Kumar Verma S. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian JBiochem. Biophys. 2012; 49: 392-4.
10. Dosen, D., Turic M. Smalcelj J., Gric MP., Separovic V. The value of frozen section in intraoperative surgical management of thyroid folicular carcinoma. Head Neck. 2003;25(7): 521-528.
11. Goldstein, R.E., Netterville J. L., Burkey B., Johnson J. E.Implications of Folicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg. 2002;235(5): 656-664.
12. McHenry C.R, Phitayakorn R. Follicular Adenoma and Carcinoma of the Thyroid Gland. Oncologist. 2011; 16: 585-593.
13. Finley DJ., Zhu B, Barden C. B., Thomas J. F. Discrimination of benign and malignant thyroid nodules by molecular profiling.Ann Surg. 2004;240(3): 425-437.
14. Sprindzuk MV. Angiogenesis in thyroid malignant neoplasm: State of the art and advances of the modern digital pathology and nanotechnology.J Clin Pathol Forensic Med.2010; 1(3): 16-34.
15. Wernicke A.G., Edgar M. A., Lavi E, Liu H, Salerno P, Bander N. H., Gutin P. H. Prostate-Specific Membrane Antigen as a potential novel vascular target for treatment of Glioblastoma Multiforme.Arch Pathol Lab Med.2011; 135: 1486-1489.
16. Itoh, A., Iwase K., Jimbo S., Yamamoto H., Kokubo M., Senda T., Nakai A., Nagagasaka T., Hibi Y., Seko T.Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg. 2010 ;34(2):242-8.
17. Ishiwata T., Iino Y., Takei H., Oyama T., Morishita Y.Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep. 1998; 5:1343-8.
18. Kusinski M., Wdzieczak-Bakala J., Liu J.M., Bignon J., Kuzdak K.AcSDKP: a new potential marker of malignancy of the thyroid gland. Langenbecks Arch Surg. 2006;391: 9-12.
19. Chang, S.S., Reuter VE., Heston WD., Bander NH., Grauer LS., Gaudin PB.Five different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies confirm PSMA exprssion in Tumor-associated neovasculature. Cancer Res.1999;59: 3192.
20. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.Cancer Res.1997; 57(17): 3629-3634.
21. Nomura N., Pastorino S., Jiang P., Lambert G., Crawford J.R., Gymnopoulos M., Piccioni D., Jaurez T., Pingle S.C., Makale M., Kesari S. Prostate_Specific Membrane Antigen expression in primary glioma and breast cancer breast metastasis.Cancer Cell Int. 2014;14(26).
22. Damle N.A., Tripathi M., Chakraborty P.S., Sahoo M. K., Bal C., Aggarwal S., Arora G., Kumar P., Kumar R., Gupta R.Unusual uptake of Prostate Specific Tracer 68Ga-PSMA-HBED-CC in a benign thyroid nodule. Nucl Med Mol Imaging. 2016; 50(4):344-347. DOI 10.1007/s13139-016-0408-y.
23. Kanthan G.L., Drummond J., Schembri G. P., Izard M.A., Hsiao E. Follicular Thyroid adenoma showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016; 41(4): 331.
24. Sager S., Vatankulu B., Uslu L., Sonmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. JNMedTechnol.2016; 44: 199-200.
25. Taywade S.K., DamleN.A., and BalC.PSMA expression in papillary thyroid carcinoma. Opening a new horizon in management of thyroid cancer? Clin Nucl Med. 2016;41(5).
26. Verburg F.A., Krohn T., Heinzel A., Mottaghy F. M., Behrendt F. F.First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur JNucl Med Mol imaging.2015; 42: 1622-1623.
27. Fenton C., Patel A., Dinauer C., Robie D. K., Tuttle R. M., Francis G. L.The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.Thyroid.2009;10(4): 349-57.
28. Nadoushan M.J., Siadati S., Amin A. A., Davati A., Mirzapour M. Study ofcorrelation between vascular endithelial groeth factor receptor and some prognostic factors in papillary carcinoma of thyroid gland. J Basic Clinpathophysiol. 2012;1(1): 1-7.
29. Silver D A. , Pellicer I., Fair WR. , HestonW.D. , Cordon-Cardo C. Prostate-Specific membrane antigen expression in normal and malignant human tissues.Clinical cancer Res.1997;3: 81-85.
30. Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R. Angiogenesis in follicular tumors of the thyroid. JSurg Oncol. 1996; 63:95-98
31. Frigugliett IC, Mello ES, Castro IV, Filho GB, Alves VA .Metalloproteinase -9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck.2001; 22(4):373-382.
32. Chaux A., Eifler J., Karram S., Al-Hussain T., Faraj S., Pomper M., Rodriguez R., George J. Netto G.Focal Positive Prostate-specific membrane antigen( SMA) expression in ganglionic tissues associated with prostate neovasculature bundle: Implication for novel intraoperative PSMA-based fluorescent imaging techniques.Urol Oncol.2011;31(5): 572-575.
33. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann F R , PenetranteR.Prostate-Specific Membrane antigen(PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumor tissue microarray technique.Histopathology. 2007;50: 472-483..
2. Kebebew E., Peng M, Reiff E, Duh Q, Clark O, McMillan A.Diagnostic and Prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.Surgery.2005;138: 1102-10.
3. Duggal R, Rajwanshi A, Gupta N, Vasishta R. K.Interobserver variability amongst cytopathologists and histopathologists in the diagnosis of neoplastic follicular patterened lesions of thyroid". Diagn Cytopathol.2011;39(4): 235-241.
4. Sanii S., Saffar H, Moradi Tabriz H, Qorbani M, Haghpanah V, Tavangar S. M.Expression of Matrix Metalloproteinase-2, but not Caspase-3, Facilitates Distinction between Benigsn and malignant thyroid follicular neoplasm.Asian PacJ Cancer Prev.2012;13:
5. Yoon JH., Kim E.K, Youk J. H., Moon H. J., Kwak J. Y. Better understanding in the differentiation of thyroid folicular adenoma , follicular carcinoma, and follicular variant of papillary carcinoma: A retrospective study.Int J Endocrinol. 2014; ID 321595: (http://dx.doi.org/10.1155/2014/321595).
6. JehS.K.,So L. J., Bum S. K., Yoen S. L. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor.Korean J Radiol. 2007;8(3): 192-197.
7. Jogai S., Adesina AO., Temmim L., Al-Jassar A., Amir T., Amanguno HG. Follicular variant of papillary thyroid carcinoma-a cytological study.Cytopathology. 2004;15(4): 212-216.
8. Vasko VV., Gaudart C, Allasia C. et al.Thyroid follicular adenomas may display features of follicular carcinoma and folicular variant of papillary carcinoma.Eur J Endocrinol.2004;151(6): 79-786.
9. Manivannan P. Siddaraju N., Jatia L., Kumar Verma S. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian JBiochem. Biophys. 2012; 49: 392-4.
10. Dosen, D., Turic M. Smalcelj J., Gric MP., Separovic V. The value of frozen section in intraoperative surgical management of thyroid folicular carcinoma. Head Neck. 2003;25(7): 521-528.
11. Goldstein, R.E., Netterville J. L., Burkey B., Johnson J. E.Implications of Folicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg. 2002;235(5): 656-664.
12. McHenry C.R, Phitayakorn R. Follicular Adenoma and Carcinoma of the Thyroid Gland. Oncologist. 2011; 16: 585-593.
13. Finley DJ., Zhu B, Barden C. B., Thomas J. F. Discrimination of benign and malignant thyroid nodules by molecular profiling.Ann Surg. 2004;240(3): 425-437.
14. Sprindzuk MV. Angiogenesis in thyroid malignant neoplasm: State of the art and advances of the modern digital pathology and nanotechnology.J Clin Pathol Forensic Med.2010; 1(3): 16-34.
15. Wernicke A.G., Edgar M. A., Lavi E, Liu H, Salerno P, Bander N. H., Gutin P. H. Prostate-Specific Membrane Antigen as a potential novel vascular target for treatment of Glioblastoma Multiforme.Arch Pathol Lab Med.2011; 135: 1486-1489.
16. Itoh, A., Iwase K., Jimbo S., Yamamoto H., Kokubo M., Senda T., Nakai A., Nagagasaka T., Hibi Y., Seko T.Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg. 2010 ;34(2):242-8.
17. Ishiwata T., Iino Y., Takei H., Oyama T., Morishita Y.Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep. 1998; 5:1343-8.
18. Kusinski M., Wdzieczak-Bakala J., Liu J.M., Bignon J., Kuzdak K.AcSDKP: a new potential marker of malignancy of the thyroid gland. Langenbecks Arch Surg. 2006;391: 9-12.
19. Chang, S.S., Reuter VE., Heston WD., Bander NH., Grauer LS., Gaudin PB.Five different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies confirm PSMA exprssion in Tumor-associated neovasculature. Cancer Res.1999;59: 3192.
20. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.Cancer Res.1997; 57(17): 3629-3634.
21. Nomura N., Pastorino S., Jiang P., Lambert G., Crawford J.R., Gymnopoulos M., Piccioni D., Jaurez T., Pingle S.C., Makale M., Kesari S. Prostate_Specific Membrane Antigen expression in primary glioma and breast cancer breast metastasis.Cancer Cell Int. 2014;14(26).
22. Damle N.A., Tripathi M., Chakraborty P.S., Sahoo M. K., Bal C., Aggarwal S., Arora G., Kumar P., Kumar R., Gupta R.Unusual uptake of Prostate Specific Tracer 68Ga-PSMA-HBED-CC in a benign thyroid nodule. Nucl Med Mol Imaging. 2016; 50(4):344-347. DOI 10.1007/s13139-016-0408-y.
23. Kanthan G.L., Drummond J., Schembri G. P., Izard M.A., Hsiao E. Follicular Thyroid adenoma showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016; 41(4): 331.
24. Sager S., Vatankulu B., Uslu L., Sonmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. JNMedTechnol.2016; 44: 199-200.
25. Taywade S.K., DamleN.A., and BalC.PSMA expression in papillary thyroid carcinoma. Opening a new horizon in management of thyroid cancer? Clin Nucl Med. 2016;41(5).
26. Verburg F.A., Krohn T., Heinzel A., Mottaghy F. M., Behrendt F. F.First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur JNucl Med Mol imaging.2015; 42: 1622-1623.
27. Fenton C., Patel A., Dinauer C., Robie D. K., Tuttle R. M., Francis G. L.The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.Thyroid.2009;10(4): 349-57.
28. Nadoushan M.J., Siadati S., Amin A. A., Davati A., Mirzapour M. Study ofcorrelation between vascular endithelial groeth factor receptor and some prognostic factors in papillary carcinoma of thyroid gland. J Basic Clinpathophysiol. 2012;1(1): 1-7.
29. Silver D A. , Pellicer I., Fair WR. , HestonW.D. , Cordon-Cardo C. Prostate-Specific membrane antigen expression in normal and malignant human tissues.Clinical cancer Res.1997;3: 81-85.
30. Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R. Angiogenesis in follicular tumors of the thyroid. JSurg Oncol. 1996; 63:95-98
31. Frigugliett IC, Mello ES, Castro IV, Filho GB, Alves VA .Metalloproteinase -9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck.2001; 22(4):373-382.
32. Chaux A., Eifler J., Karram S., Al-Hussain T., Faraj S., Pomper M., Rodriguez R., George J. Netto G.Focal Positive Prostate-specific membrane antigen( SMA) expression in ganglionic tissues associated with prostate neovasculature bundle: Implication for novel intraoperative PSMA-based fluorescent imaging techniques.Urol Oncol.2011;31(5): 572-575.
33. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann F R , PenetranteR.Prostate-Specific Membrane antigen(PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumor tissue microarray technique.Histopathology. 2007;50: 472-483..
Downloads
Published
27-10-2017
How to Cite
1.
Saffar H, kiany M, Tavangar SM, Mirzaian E. Expression of PSMA in Thyroid follicular neoplasms: Utility for differentiating between benign from malignant lesions. Ann of Pathol and Lab Med [Internet]. 2017 Oct. 27 [cited 2024 Nov. 19];4(5):A541-545. Available from: https://pacificejournals.com/journal/index.php/apalm/article/view/apalm1511
Issue
Section
Original Article
License
Copyright (c) 2017 Hiva Saffar, Marzieh kiany, Seyed Mohammad Tavangar, Elham Mirzaian
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).